Inactive Instrument

Analyst Reco. ACLS THER Nasdaq

Equities

End-of-day quote Nasdaq Other stock markets
- ^USD	-

07-16	Aclaris Therapeutics Sells Olumiant Royalties, Milestone Payments From Eli Lilly	MT
07-05	Aclaris Therapeutics Insider Bought Shares Worth $405,894, According to a Recent SEC Filing	MT

Analyst Reco.

Aclaris Therapeutics Insider Bought Shares Worth $405,894, According to a Recent SEC Filing	07-05	MT
Aclaris Therapeutics Insider Bought Shares Worth $1,742,075, According to a Recent SEC Filing	07-01	MT
HC Wainwright Downgrades Aclaris Therapeutics to Neutral From Buy	01-22	MT
BTIG Downgrades Aclaris Therapeutics to Neutral From Buy	01-11	MT
Stifel Trims Price Target on Aclaris Therapeutics to $1 From $2, Maintains Hold Rating	12-18	MT
HC Wainwright Cuts Price Target on Aclaris Therapeutics to $9 From $43, Maintains Buy Rating	11-14	MT
Cantor Fitzgerald Downgrades Aclaris Therapeutics to Neutral From Overweight	11-14	MT
Evercore ISI Cuts Aclaris Therapeutics' Price Target to $3 From $22, Keeps Outperform Rating	11-13	MT
Piper Sandler Downgrades Aclaris Therapeutics to Neutral From Overweight, Cuts Price Target to $2 From $30	11-13	MT
Stifel Downgrades Aclaris Therapeutics to Hold From Buy, Cuts Price Target to $2 From $20	11-13	MT
William Blair Downgrades Aclaris Therapeutics to Market Perform From Outperform	11-13	MT
Evercore ISI Initiates Aclaris Therapeutics at Outperform Rating With $22 Price Target	03/10/23	MT
Stifel Adjusts Price Target on Aclaris Therapeutics to $20 From $16, Maintains Buy Rating	14/09/23	MT
Goldman Sachs Adjusts Price Target on Aclaris Therapeutics to $21 From $25, Maintains Buy Rating	07/03/23	MT
HC Wainwright Adjusts Price Target on Aclaris Therapeutics to $43 From $50, Maintains Buy Rating	07/03/23	MT
BTIG Research Adjusts Aclaris Therapeutics Price Target to $29 From $32, Maintains Buy Rating	07/03/23	MT
Stifel Nicolaus Initiates Coverage on Aclaris Therapeutics With Buy Rating, $29 Price Target	14/12/22	MT
Goldman Sachs Initiates Aclaris Therapeutics at Buy With $25 Price Target	01/12/22	MT
BTIG Starts Aclaris Therapeutics at Buy With $32 Price Target	06/10/22	MT
ACLARIS THERAPEUTICS : HC Wainwright Adjusts Price Target on Aclaris Therapeutics to $50 From $40, Reiterates Buy Rating	16/06/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. ACLS THER Nasdaq

Equities

Analyst Reco.

Filters